Antimicrobial susceptibility of gram-negative strains isolated from bloodstream infections in China: Results from the study for monitoring antimicrobial resistance trends (SMART) 2018–2020
Open Access
- 21 March 2025
- journal article
- research article
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 153, e48
Abstract
The study aims were to present in vitro susceptibilities of clinical isolates from Gram-negative bacteria bloodstream infections (GNBSI) collected in China. GNBSI isolates were collected from 18 tertiary hospitals in 7 regions of China from 2018 to 2020. Minimum inhibitory concentrations were assessed using a Trek Diagnostic System. Susceptibility was determined using CLSI broth microdilution, and breakpoints were interpreted using CLSI M100 (2021). A total of 1,815 GNBSI strains were collected, with E. coli (42.4%) and Klebsiella pneumoniae (28.6%) being the most prevalent species, followed by P. aeruginosa (6.7%). Susceptibility analyses revealed low susceptibilities (E. coli and K. pneumonia to third-/fourth-generation cephalosporins, monobactamases, and fluoroquinolones. High susceptibilities to colistin (95.0%) and amikacin (81.3%) were found for K. pneumoniae, while Acinetobacter baumannii exhibited a high susceptibility (99.2%) to colistin but a low susceptibility to other antimicrobials (K. pneumoniae and A. baumannii than isolates from non-ICUs (all P < 0.05). Carbapenem-resistant and ESBL-producing K. pneumoniae detection was different across regions (both P < 0.05). E. coli and K. pneumoniae were major contributors to GNBSI, while A. baumannii exhibited severe drug resistance in isolates obtained from ICU departments.Keywords
This publication has 30 references indexed in Scilit:
- In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumanniiEuropean Journal of Clinical Microbiology & Infectious Diseases, 2022
- Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort studyThe Lancet Infectious Diseases, 2022
- Regional differences in carbapenem-resistant Klebsiella pneumoniaeThe Lancet Infectious Diseases, 2022
- Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases PharmacistsInfectious Diseases and Therapy, 2021
- Treatment of patients with serious infections due to carbapenem‐resistant Acinetobacter baumannii: How viable are the current options?Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2021
- Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitalsThe Lancet Infectious Diseases, 2020
- Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China, 2008–2018Emerging Microbes & Infections, 2020
- Bloodstream infections in the elderly: what is the real goal?Aging Clinical and Experimental Research, 2019
- Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropeniaClinical Microbiology and Infection, 2016
- Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitalsClinical Microbiology and Infection, 2016